SG149051A1 - Nicotinic acetylcholine receptor ligands - Google Patents
Nicotinic acetylcholine receptor ligandsInfo
- Publication number
- SG149051A1 SG149051A1 SG200809494-8A SG2008094948A SG149051A1 SG 149051 A1 SG149051 A1 SG 149051A1 SG 2008094948 A SG2008094948 A SG 2008094948A SG 149051 A1 SG149051 A1 SG 149051A1
- Authority
- SG
- Singapore
- Prior art keywords
- acetylcholine receptor
- receptor ligands
- nicotinic acetylcholine
- psychotic
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53164803P | 2003-12-22 | 2003-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG149051A1 true SG149051A1 (en) | 2009-01-29 |
Family
ID=34710243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200809494-8A SG149051A1 (en) | 2003-12-22 | 2004-12-20 | Nicotinic acetylcholine receptor ligands |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070191422A1 (fr) |
| EP (1) | EP1699787A1 (fr) |
| JP (1) | JP2007515481A (fr) |
| KR (1) | KR20060123365A (fr) |
| CN (1) | CN1914200A (fr) |
| AU (1) | AU2004303740A1 (fr) |
| BR (1) | BRPI0417933A (fr) |
| CA (1) | CA2550847A1 (fr) |
| IL (1) | IL176073A0 (fr) |
| MX (1) | MXPA06007024A (fr) |
| NO (1) | NO20063331L (fr) |
| SG (1) | SG149051A1 (fr) |
| WO (1) | WO2005061495A1 (fr) |
| ZA (1) | ZA200605024B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US7928264B2 (en) * | 2004-09-21 | 2011-04-19 | Astellas Pharma Inc. | Aminoalcohol derivatives |
| JP5996532B2 (ja) * | 2010-07-15 | 2016-09-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 有害生物防除剤としての新規複素環式化合物 |
| KR101928505B1 (ko) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US6500840B2 (en) * | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| WO2002015662A2 (fr) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies |
| EP1311505A2 (fr) * | 2000-08-21 | 2003-05-21 | PHARMACIA & UPJOHN COMPANY | Fragments heteroaryle a substitution quinuclidine destines au traitement de maladies |
| DE10156719A1 (de) * | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
-
2004
- 2004-12-20 BR BRPI0417933-1A patent/BRPI0417933A/pt not_active IP Right Cessation
- 2004-12-20 KR KR1020067012363A patent/KR20060123365A/ko not_active Application Discontinuation
- 2004-12-20 AU AU2004303740A patent/AU2004303740A1/en not_active Abandoned
- 2004-12-20 JP JP2006546911A patent/JP2007515481A/ja not_active Abandoned
- 2004-12-20 CN CNA2004800412792A patent/CN1914200A/zh active Pending
- 2004-12-20 MX MXPA06007024A patent/MXPA06007024A/es unknown
- 2004-12-20 SG SG200809494-8A patent/SG149051A1/en unknown
- 2004-12-20 WO PCT/SE2004/001943 patent/WO2005061495A1/fr active Application Filing
- 2004-12-20 US US10/583,581 patent/US20070191422A1/en not_active Abandoned
- 2004-12-20 CA CA002550847A patent/CA2550847A1/fr not_active Abandoned
- 2004-12-20 EP EP04809116A patent/EP1699787A1/fr not_active Withdrawn
-
2006
- 2006-05-31 IL IL176073A patent/IL176073A0/en unknown
- 2006-06-19 ZA ZA200605024A patent/ZA200605024B/en unknown
- 2006-07-18 NO NO20063331A patent/NO20063331L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0417933A (pt) | 2007-04-17 |
| KR20060123365A (ko) | 2006-12-01 |
| NO20063331L (no) | 2006-09-20 |
| US20070191422A1 (en) | 2007-08-16 |
| CN1914200A (zh) | 2007-02-14 |
| IL176073A0 (en) | 2006-10-05 |
| ZA200605024B (en) | 2007-04-25 |
| WO2005061495A1 (fr) | 2005-07-07 |
| MXPA06007024A (es) | 2006-08-31 |
| EP1699787A1 (fr) | 2006-09-13 |
| AU2004303740A1 (en) | 2005-07-07 |
| JP2007515481A (ja) | 2007-06-14 |
| CA2550847A1 (fr) | 2005-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200613243A (en) | Novel compounds | |
| TW200508214A (en) | Novel compounds | |
| SE0200920D0 (sv) | Novel compounds | |
| TNSN05194A1 (en) | Substituted n-arylheterocycles, method for production and use thereof as medicaments | |
| IL229136A (en) | Process for making mek inhibitors | |
| NO20050525L (no) | Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| DE602004021472D1 (en) | Pyrimiidinverbindungen | |
| SE0202539D0 (sv) | Compounds | |
| TW200738659A (en) | Novel compounds | |
| TW200616995A (en) | Novel compounds | |
| EP1633740A4 (fr) | Composes chimiques | |
| MXPA05008690A (es) | Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| TW200640908A (en) | Chemical compounds | |
| TW200800999A (en) | Novel compounds | |
| TW200621751A (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
| SE0104140D0 (sv) | Novel Compounds | |
| ZA200707901B (en) | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| GEP20115231B (en) | 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones | |
| TW200724537A (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
| TW200639156A (en) | New compounds | |
| TW200635916A (en) | Compounds | |
| MY135850A (en) | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | |
| TNSN07440A1 (en) | Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same | |
| TW200604197A (en) | New compounds |